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Abstract: The small molecules, natural antioxidant Caffeic Acid (trans-3,4-Dihydroxycinnamic
acid CA) and anti-diabetic drug Metformin (Met), activate 5′-adenosine monophosphate-activated
protein kinase (AMPK) and interfere with metabolic reprogramming in human cervical squamous
carcinoma cells. Here, to gain more insight into the ability of CA, Met and the combination of both
compounds to impair aerobic glycolysis (the “Warburg effect”) and disrupt bioenergetics of cancer
cells, we employed the cervical tumor cell lines C-4I and HTB-35/SiHa. In epithelial C-4I cells
derived from solid tumors, CA alleviated glutamine anaplerosis by downregulation of Glutaminase
(GLS) and Malic Enzyme 1 (ME1), which resulted in the reduction of NADPH levels. CA treatment
of the cells altered tricarboxylic acid (TCA) cycle supplementation with pyruvate via Pyruvate
Dehydrogenase Complex (PDH), increased ROS formation and enhanced cell death. Additionally,
CA and CA/Met evoked intracellular energetic stress, which was followed by activation of AMPK
and the impairment of unsaturated FA de novo synthesis. In invasive HTB-35 cells, Met inhibited
Hypoxia-inducible Factor 1 (HIF-1α) and suppressed the expression of the proteins involved in the
“Warburg effect”, such as glucose transporters (GLUT1, GLUT3) and regulatory enzymes of glycolytic
pathway Hexokinase 2 (HK2), 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 4 (PFKFB4),
Pyruvate Kinase (PKM) and Lactate Dehydrogenase A (LDH). Met suppressed the expression of
c-Myc, BAX and cyclin-D1 (CCND1) and evoked apoptosis in HTB-35 cells. In conclusion, both
small molecules CA and Met are capable of disrupting energy homeostasis, regulating oxidative
metabolism/glycolysis in cervical tumor cells in regard to specific metabolic phenotype of the cells.
CA and Met may provide a promising approach in the prevention of cervical cancer progression.
Keywords: cancer metabolism; metabolic reprogramming; cervical cancer; Warburg effect; 5′-adenosine
monophosphate-activated protein kinase (AMPK); Caffeic Acid; Metformin; polyphenols; mitochondria
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1. Introduction
Recently, the reprogramming of cancer cell metabolism has been acknowledged as a promising
target for pharmacological interventions [1]. The inhibition of selected key points regulating
biosynthetic pathways with regard to specific metabolic phenotype of tumor cell may help to establish
specific anticancer approaches [2,3]. The activation of main sensor of energy status 5′-adenosine
monophosphate-activated protein kinase (AMPK) by acting on cell cycle checkpoints and suppressing
biosynthesis influences cell survival [4]. Depending on cellular context, the activation or silencing
of AMPK regulates metabolic pathways which in turn affects proliferation of neoplastic cells [5].
The role of AMPK in cervical cancer development and progression has been only partially recognized.
However, emerging data have suggested, that relevant manipulation of AMPK signaling in tumors
may selectively induce cell death.
The anticancer potential of small molecules that can interfere with cellular bioenergetics by depletion
of ATP and regulate biosynthetic processes via AMPK signaling have been recently intensively studied.
Several natural compounds, such as Caffeic Acid (trans-3,4-Dihydroxycinnamic acid, CA), were reported
to act via AMPK signaling [6]. CA is a major representative of hydroxycinnamic acids and appears in
plants mainly as Chlorogenic Acid (5-caffeoylquinic acid, an ester of Caffeic Acid with Quinic Acid) [7].
Anti-tumor effects of CA have been recently demonstrated in breast cancer cells [8]. In colorectal carcinoma
cells CA derivatives, involving the activation of AMPK and its downstream targets, inhibited the growth
of cancer cells by modulation of phosphatidylinositide 3-kinases (PI3-K)/Akt and mammalian target
of rapamycin (m-TOR) signaling pathways [9,10]. Biguanide Metformin (Met), has been reported to
inhibit proliferation of numerous cancer cell lines [11,12]. Met was shown to decrease tumor growth and
metastasis formation in animal models as well as in humans [13,14]. Mechanistic study revealed, that Met
affects energy metabolism and exerts its effect by inhibition of Complex I of Electron Transport Chain
(ETC) in mitochondria, which results in ATP depletion and remodeling of the network of biosynthetic
processes within the cell [15]. Emerging data suggest that CA as well as Met can synergize with targeted
anticancer therapies and enhance therapeutic response to drugs in specific tumor types [11,16–18].
The current strategies against cervical malignancy are being developed with regard not only
to specific genetic background but also to metabolic specificity of cancer cells [19–21]. Numerous
studies have shown that aerobic glycolysis generates ATP and provides substantial amounts of
energy for aggressive tumors without excessive generation of Reactive Oxygen Species (ROS) [22].
Recently, we have found that HTB-35 cervical squamous carcinoma cells exhibit invasive phenotype
and upregulated expression of mesenchymal genes [23], thus in the present study we aimed to explore
whether CA and/or Met may influence the regulation of glycolytic pathway within HTB-35 cells. Since
the activation of oncogene c-Myc and Hypoxia-inducible Factor 1 (HIF-1α) may trigger expression of
glycolytic genes, we tested if CA and Met affect the expression of c-Myc and the function of HIF1-α
in cells cultured in normoxic as well as hypoxic conditions. Furthermore, in order to find out how
the drugs regulate mitochondrial metabolism of tumor cells with epithelial phenotype, we employed
human cervical squamous carcinoma cell line C-4I, derived from in situ tumor, which expresses high
genetic and metabolic agreement with cervical cancer biopsies [23,24]. Previously we demonstrated
that CA and Met are capable of regulating mitochondrial TCA cycle supply in HTB-35 cell [18] and
in HTB-34 cells derived from metastatic site [25]. Here, using C-4I cells we investigated, whether the
regulation of pyruvate/glutamine-based supply of tricarboxylic acid (TCA) cycle may be relevant
metabolic hot spot to affect cellular bioenergetics and biosynthetic pathways in epithelial tumor
cells and we tested if such intervention results in the suppression of ATP/NADPH synthesis and
further elimination of cervical cancer cells. As CA activated AMPK in HTB-35 cells, which undergo
Epithelial-to-Mesenchymal Transition (EMT) [18] and in HTB-34 cells [25], which undergo EMT and
subsequent Mesenchymal-to-Epithelial Transition (MET), we aimed to elucidate if CA and/or Met
activate AMPK and regulate de novo synthesis/desaturation of fatty acids (FA) in C-4I tumor cells.
We discussed the possibility of application of CA, Met and co-treatment as a therapeutic strategy for
counteracting proliferation of cervical cancer with regard to bioavailability of tested compounds.
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2. Materials and Methods
2.1. Cell Culture
Both cell lines C-4I (ATCC designation CRL-1594, human) and HTB-35 (ATCC designation HTB-35,
SiHa, human) were derived from the American Type Cell Culture collection. C-4I line was maintained
at 37 ◦C as a monolayer culture in Waymouth’s MB 752⁄1 medium (Life Technologies, New York,
NY, USA). HTB-35 cells were grown in Dulbecco’s modified Eagle’s medium (Lonza, Walkersville,
MD, USA) in atmosphere of 5% CO2, unless otherwise noted. 10% v/v FBS (Eurex Sp z o.o., Gdansk,
Poland) was used for media supplementation. 50 µg/mL of gentamicin was added to culture media
(Sigma-Aldrich, Seelze, Germany). Cells up to the 25th passage were used. Trypsin-EDTA solution
was used for subcultures. C-4I were seeded at a density of 2.5 × 105 cells/mL and HTB-35 cells were
seeded at a density of 1 × 105 cells/mL into the 6-well plates (Sarstedt, Numbrecht, Germany) and
incubated to archive the sufficient confluency for experiments. The cells were kept for 24 h in medium
containing 0.5% v/v of bovine serum albumin (BSA, Sigma-Aldrich) and antibiotic. Then medium was
changed for the new one serum-free Waymouth’s/0.5% BSA with adequate volumes of a stock solution
of Met (10 mM, Sigma-Aldrich), CA (100 µM, Sigma-Aldrich) or Met (10 mM) and CA (100 µM)
together. The cells were exposed to compounds for 24 h. The solvents of Met (PBS, Lonza) and
CA (dimethyl sulfoxide, DMSO, 1% v/v, Sigma-Aldrich) were added to appropriate control wells.
Each experiment was repeated three times. The cells as well as media were collected after each
experiment. The automatic cell counter Countess (Gibco Laboratories, Grand Islands, NY, USA) was
used for a precise measurement of cells number. The inverted light microscope Olympus CKX 41SF-5
(Olympus, Germany) was used for the inspection of the morphology of cell culture.
2.2. Flow Cytometry Analyses
For flow cytometry analyses, C-4I cells were plated in 6-well plates (Sarstedt) in triplicates at a
density of 2.5 × 105 cells per well. After exposure for 24 h to CA, Met and CA/Met, the cells were
detached using Trypsin-EDTA solution, washed with buffered PBS (Lonza, Walkersville, MD, USA)
and centrifuged at 350× g for 5 min. Then the cells were suspended in binding buffer at a room
temperature. Fluorescent dyes, 488-AnnexinV (Biotium, Hayward, CA, USA; excitation maximum
at 490 nm/emission maximum at 515 nm) and/or Ethidium homodimer (EthD-III, Biotium, CA,
USA; excitation maximum at 528 nm/emission maximum at 617 nm) were added to cells’ suspension
according to the manufacturer’s procedure. In order to correct discrimination between cells and debris,
SYTO 41 Blue Fluorescent Nucleic Acid Stain was used (excitation maximum at 483 nm/emission
maximum at 503 nm). The appropriate controls fluorescence minus one were prepared. The cells
were incubated in dark for 15 min and acquired flow cytometer FACSCanto10C with BD FACSCanto
System Software (BD Biosciences Immunocytometry Systems, San Jose, CA, USA). The cells were
gated according to forward (FSC), side scatter (SSC) and fluorescence parameters (FITC channel was
used for 488-AnnexinV and Texas Red channel was used for EthD-III). The details of analysis were
described in [26]. The results were given as the percentage of apoptotic or necrotic cells of total counted
cells. Simultaneously, the generation of mitochondrial superoxide was measured with MitoSox Red
reagent (Invitrogen, CA, USA; excitation maximum at 510 nm/emission maximum at 580 nm) using
FACSCanto10C cytometer (BD Biosciences). The cells were incubated for 10 min at 37 ◦C with 5 µM of
reagent working solution prepared in DMSO.
2.3. Immunoblots
Cells for immunoblot analysis were incubated with appropriate concentrations of compounds
in 6-well plates (Sarstedt) and homogenized in M-PER buffer (4 ◦C, Thermo Fisher Scientific Inc.,
Waltham, MA, USA). A mixture of water-soluble protease inhibitors (Merck, Darmstadt, Germany)
was used to prevent proteolytic degradation of protein samples during cell lysis and extraction. Protein
extracts were mixed with 4 Laemmli sample buffer and heated for 10 min., loaded onto an SDS gel,
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resolved via standard SDS-PAGE and, finally, transferred to PVDF membranes for Western blotting.
The buffer used for membranes blocking with 1% BSA in Tris Buffered Saline with Tween 20 (TBST,
pH 7.5). TBST contained 20 mM of Tris-hydrochloride, 0.05% Tween 20 and 150 mM NaCl (BioRad,
Laboratories, Richmond, CA, USA), as earlier reported [18,25]. After being blocked, the membranes
were probed for 12 h in buffer with addition of 1% BSA, 0.1% Tween 20 and the appropriate primary
antibody. The immunodetection was performed using primary antibodies obtained from the following
sources: anti-AMPK (Cell signaling, Danvers, MA, USA), anti-p-AMPK (Cell signaling), anti-p-PDH
(Abcam, Cambridge, MA, USA), anti-PDH (Cell signaling), anti-CPT1 (Cell signaling), anti-GLUT1
(Santa Cruz Biotech., Santa Cruz, CA, USA), anti-p-ACC1 (Cell signaling), anti-ACC1 (Cell signalling)
anti-ACLY, anti-FAS (Santa Cruz Biotech.), anti-SCD1(Santa Cruz Biotech.), anti-PDK-1 (Sigma-Aldrich,
St Louis, MO, USA), anti-HK2 (Santa Cruz Biotch), anti-PKM2 (Sigma-Aldrich, MO, USA), anti-GLUT3
(Sigma-Aldrich, MO, USA) and anti-PFKFB4 (Abcam, MA, USA). β-actin (Cell signaling) was applied
as the control of the loading process. The secondary antibodies conjugated to the horseradish
peroxidase were from Santa Cruz Biotech. The protein expression was assayed using the Super
Signal West Pico Chemiluminescent Substrate Kit, Pierce Chemical, Rockford, IL, USA). Gel Logic
Imaging System 1500 (Kodak; Molecular imaging System Corestea Health Inc., Rochester, NY, USA)
was used for the detection and analysis of the chemiluminescence signal. Bradford method was used
for the measurement of the total protein amount, as described elsewhere. For HIF-1α analysis total
protein was measured by of Lowry assay with modification of Peterson [23].
2.4. Pyruvate Dehydrogenase Kinase (PDK) Activity Assay
C-4I cells were exposed to Met, CA and Met/CA as described in Section 2.1. and then
mitochondria were isolated from cells and processed as described previously [25]. For the assay, 20 mM
Tris-hydrochloride buffer (pH 7.4; 2 mM EGTA, 5 mM K2HPO4, 120 mM KCl) containing 10 µM of
uncoupler carbonyl cyanide-chlorophenylhydrazone (CCCP, Sigma-Aldrich) was used. The extraction
buffer contained 0.5% v/v Triton-X100, 2 mM DTT, 50 mM K2HPO4, 10 mM EGTA, and 1% v/v BSA
(Sigma-Aldrich). PDK activity was expressed as the rate of ATP-dependent inactivation of PDH
complex and calculated as the apparent first-order rate constant.
2.5. Quantitation of NADP and NADPH Levels
Cells at a density of 2.5 × 105 cells/mL were seeded in T-75 plates (Sarstedt), cultured and
incubated with CA, Met and Met/CA for 24 h. Then the cells were harvested and homogenized
according to manufacturer’s protocol. NADPH colorimetric quantitation kit was used to assess the
intracellular concentrations of NADPH following deprotenization of samples by filtering through a
10 kDa cut-off filters. The absorbance was measured at 450 nm using microplate reader Infinite M200
Pro (Tecan, Salzburg, Austria).
2.6. Quantitation of ATP and ADP Levels
C-4I cells were placed in 96-well microtiter plate (Sarstedt) at a density of 2.5 × 104 cells per well,
cultured and then exposed to CA, Met and Met/CA co-treatment for 24 h. ADP/ATP ratio assay kit
was employed to measure intracellular concentration of ATP and ADP in each sample. The procedure
was conducted according to manufacturer’s protocol and luminescence (relative light units) was read
using microplate reader (Tecan, Salzburg, Austria).
2.7. Hypoxia Conditions
The cells were seeded into plates (C4-I cells at a density of 2.5 × 105 cells/mL and HTB-35 cells
at a density of 1 × 105 cells/mL) and cultivated in atmosphere of 5% CO2 at 37 ◦C until desired cell
confluence was reached. Then the cells were exposed to CA, Met and CA/Met for 24 h under normoxic
(oxygen concentration 21%) or hypoxic conditions (oxygen concentration 5%; a gas mixture contained
Nutrients 2018, 10, 841 5 of 21
5% CO2 and a balance of nitrogen). The cells were kept in Panasonic MCO-170M-PE incubator (Gunma,
Japan). Then the cells were harvested for RNA isolation [23].
2.8. Quantitative Polymerase Chain Reaction (qPCR)
Prior to RNA isolation, the cells were detached with a rubber policeman, centrifuged and
suspended in RL buffer (EURx, Gdansk, Poland). Afterward the total RNA was extracted using
Universal RNA purification Kit (EURx, Gdansk, Poland), according to the manufacturer’s protocol.
MMLV reverse transcriptase (Promega, Madison, WI, USA) was used for cDNA synthesis. The reverse
transcription reaction was performed with ProFlex PCR System (Applied Biosystems, Foster City, CA,
USA). The QuantStudio 7 Flex (Applied Biosystems, Foster City, CA, USA) was employed for the
real-time qPCR. Blank qPCR Master Mix (EURx) and the following Taq-Man human probes (Applied
Biosystems) were used: HIF1A (Hs00153153_m1), MYC-C (Hs00905030_m1), BCL2 (Hs00153350_m1),
BAX (Hs001802669_m1), CCND1 (Hs00277039_m1) and GAPDH (Hs99999905_m1). The obtained data
were normalized against GAPDH transcript as a reference gene and levels of RNA expression were
determined with the 2−∆∆Ct method.
2.9. Unsaturated Fatty Acid Content
C4-I cells were exposed to CA, Met and CA/Met for 24 h, washed with buffered PBS (Lonza) and
collected. Previous to the unsaturated fatty acid assay, the organic extraction of total lipids from the
cells was performed according to the manufacturer’s protocol using Chloroform-free Lipid Extraction
Kit (Cell Biolabs Inc., San Diego, CA, USA). Then content of unsaturated fatty acids in cells was
measured with sulfo-phospho-vanillin method using commercially available colorimetric kit (Cell
Biolabs Inc.). Briefly, the samples were treated with 18M sulfuric acid and incubated for 10 min at
90 ◦C and then for 5 min were kept in 4 ◦C. Then vanillin reagent was added to each sample and the
mixture was incubated for 15 min at 37 ◦C. The absorbance was measured at 550 nm using Bio-Tek
microplate reader (the background was subtracted from signal).
2.10. MTT Assay
Cell proliferation was detected by MTT (3-[4,5-dimethylthiazol-2yl]-2,5-diphenyl tetrazolium
bromide purchased from Sigma-Aldrich (Seelze, Germany). C4-I exponentially dividing cells
(2.5 × 105 cells/mL) were grown in 96-well microtiter plate (Sarstedt, Numbrecht, Germany) in
serum-free medium. For each experiment, the positive controls (the untreated cells cultured in
medium with addition of appropriate solvent) were prepared. After incubation with compounds,
the medium was removed and replaced with the new one, containing 0.5% w/v MTT. The formazan
crystals generated during incubation were dissolved in DMSO and absorbance was recorded at 570 nm
(the reference wavelength was 630 nm), as described previously [18,25]. Microplate reader (Tecan,
Salzburg, Austria) was used for absorbance measurement. The relative cellular growth was determined
by a ratio of average absorbance in cells exposed to tested compounds versus the average absorbance
in untreated cells.
2.11. LDH Assay
Lactate Dehydrogenase (LDH) leakage assay was used to detect the cytotoxicity of CA, Met
and co-treatment in culture of C4-I cells. LDH is elevated in media following incubation of the cells
with cytotoxic agents. For LDH test, the cells were seeded into 96-well plates (Sarstedt) and exposed
to drugs as described in Section 2.11. The commercially available kit from Biolabo S.A. (France)
was used to measure LDH leakage from cells exposed to the tested compounds. The LDH test was
performed according to the manufacturer’s protocol and the LDH level in medium was quantified by
an enzymatic reaction of the conversion of pyruvate and lactate with subsequent reduction of NAD+
to NADH. The concentration of generated NADH was measured at 340 nm using microplate reader
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(Tecan, Austria). The results were calculated as the percentage of LDH in the medium versus total
LDH activity in the cells.
2.12. Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
The cells were incubated as described in Section 2.7 and subsequently lysed. Initially, cell
lysate was spun through the spin column eliminating the genomic DNA and then total RNA was
purified with silica-membrane RNeasy spin columns (Qiagen, Hilden, Germany). Next, the isolated
RNA was subjected to measurement using NanoDrop ND-1000 Spectrophotometer (Nano Drop
Technologies, Wilmington, DE, USA). For cDNA synthesis 1ug of total RNA was used. Synthesis
of cDNA was carried out using the oligodT starter and GoScript Reverse Transcriptase (Promega
GmbH, Mannheim, Germany). The PCR reaction mixture was composed of 1.5 uL of cDNA, 0.2 mM
dNTPs (Sigma Aldrich), 0.2 µM of each primer (Sigma Aldrich), 2.5 mM Magnesium Chloride
(Sigma Aldrich), 1.25 U JumpStart™ Taq DNA Polymerase (Sigma Aldrich and 1× PCR buffer
(Sigma Aldrich) in final volume 25 µL. Amplification of cDNA with the specific primers was
performed in Research PTC-200 Thermal Cycler. Primers used were: SLC2A1 (Solute carrier family 2,
facilitated glucose transporter member 1, GLUT1) forward (5-TTGGCTCCGGTATCGTCAAC-3),
SLC2A1 reverse (5-GGTCCGGCCTTTAGTCTCAG-3), SLC2A3 (Solute carrier family 2, facilitated
glucose transporter member 1, GLUT3) forward (5-GTGCACTGTCACTTTGCTCTG-3), SLC2A3
reverse (5-AACCTACTGTTTGAGGAGCCAG-3), HK2 (hexokinase 2) forward (5-TCACGGAG
CTCAACCATGAC-3), HK2 reverse (5-CTGCAGTAGGGTGAGTGGTG-3), ALDOA (Aldolase A)
forward (5-GAGAACACCGAGGAGAACCG-3), ALDOA reverse (5-TGGGTGGTAGTCTCGCCATT-3),
ENO1 (enolase 1) forward (5-ATGGTGTCTCATCGTTCGGG-3), reverse (5-TGAGGAGCTGGTTG
TACTTGG-3), PKM (pyruvate kinase M1/2) forward (5-GCCGCCTGGACATTGATTC-3),
reverse (5-CCATGAGAGAAGTTCAGACGAG-3), PDK1 (pyruvate dehydrogenase 1) forward
(5-CGGATCAGAAACCGACACAA-3), reverse (5-AGATGGACTTCCTTTGCCTTTTC-3), PFKFB4
(6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 4) forward (5-GGGATGGCGTCC CCACGGG-3),
PFKFB4 reverse (5-CGCTCTCCGTTCTCGGGTG-3), LDHA (Lactate Dehydrogenase A) forward
(5-CTGTTCCACTTAAGGCCCCTC-3), LDHA reverse (5-CCAGCCTTTCCC CCATTAGG-3), HPRT1
(Hypoxanthine-Guanine Phosphoribosyltransferase) forward (5-TGGCGTCGT GATTAGTGATG-3),
HPRT1 reverse (5-TATCCAACACTTCGTGGGGT-3). The condition for PCR reaction was as following;
5 min of denaturation at 95 ◦C, next 30 s annealing at 58 ◦C and 30 s extension at 72 ◦C. The final
extension was performed at 72 ◦C for 10 min. Amplification for 30 cycles was applied for all PCR
products with subsequent visualization on the agarose gel (1.5% w/v). HPRT gene was used as
housekeeping gene for normalization purpose.
2.13. Statistical Analysis
The data were expressed as mean ± SD. The statistical significance of the obtained raw data was
analyzed using one-way ANOVA and followed by Duncan post-hoc test (p values < 0.05, p < 0.01,
p < 0.001) using the commercially available packages Statistica PL v.10 (StatSoft, Tulsa, OK, USA).
3. Results
3.1. CA Treatment Impairs Glutaminolysis by Downregulation of Glutaminase (GLS) and Decreases NADPH
Level in C-4I Cells
The effect of Met and CA on glutamine anaplerosis in C-4I cells was evaluated by estimating
capability of drugs to influence the expression of GLS. CA treatment at a concentration of 100 µM for
24 h decreased GLS protein amount, while Met at 10 mM caused minor upregulation of the enzyme
(Figure 1A, p < 0.05 vs. untreated control). CA decreased the expression of Malic Enzyme 1 (ME1)
protein amount and thus we determined whether the incubation of cells with the drug may influence
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the intracellular NADPH level. The obtained results indicated that CA alone and co-treated with Met
caused significant reduction of NADPH content in C-4I cells (Figure 1B, p < 0.05 vs. untreated control).
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Figure 1. The effect of Caffeic Acid (CA) and Metformin (Met) on Glutaminase (GLS) and Malic
Enzyme 1 (ME1) expression and NADPH level in C-4I cells. The cells were treated with CA (100 µM)
and/or Met (10 mM) for 24 h in serum-free medium. The exposition of cells to CA decreased GLS and
ME1 expression (A) (* p < 0.05 vs. untreated control) Protein levels of GLS and ME1 were analyzed
by Western blot, as described in Materials and Methods. CA caused decrease of NADPH level in C-4I
cells, as measured spectrophotometrically (B). Data presented are representative of those obtained in
three separate experiments.
3.2. CA Regulates TCA Cycle Supply via Pyruvate Dehydrogenase Complex (PDH), Induces Mitochondrial
ROS Generation and Evokes Apoptosis in C-4I Cells
As shown in Figure 2A, CA promoted the process of oxidative decarboxylation of pyruvate in C-4I
cells by dephosphorylation of PDH complex at S293 residue (p < 0.05 vs. untreated control). To explore
the mechanism of the PDH inhibition, we tested whether the drug affects the activity of Pyruvate
Dehydrogenase Kinase (PDK). PDK phosphorylates and thereby inactivates PDH complex. Exposition
of cells to CA at a concentration of 100 µM caused inhibition of PDK activity, as demonstrated in
Figure 2B, (p < 0.05 vs. untreated control).
To explore whether C-4I cells exposed t CA for 24 h become more vulnerable to oxidative stress,
MitoSox staining followed by cytometry analysis was used. Single treatment of the cells with CA
significantly increased ROS level in mitochondria, compared to untreated control ((Figure 3A; p < 0.05),
while Met itself caused no statistically significant effect (p < 0.05 vs. untreated control). Using flow
cytometry, we also determined that apoptosis was the supreme way of death of cells incubated with
CA. The percentage of apoptotic cells after CA and Met/CA treatment was significantly higher than in
population of untreated or Met-treated cells, as presented in Figure 3B (p < 0.01 for CA and Met/CA
vs. untreated control, p < 0.01 for Met/CA vs. Met). The number of apoptotic cells in population after
CA treatment was significantly higher than corresponding amount in population of Met/CA-treated
cells (p < 0.05 for CA vs. Met/CA).
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Figure 2. The effect of Caffeic Acid (CA) and Metfor in (Met) on pyruvate decarboxylation via
Pyruvate Dehydrogenase Complex (PDH) in C-4I cells. The cells were exposed in serum-free medium
to CA (100 µM) and/or Met (10 mM) for 24 h. Protein level was assayed by Western blot as described in
Materials and Methods and followed by chemiluminescent detection. β-actin was used as the protein
loading control (A). Note that CA, unlike Met and Met/CA, caused PDH-E1α phosphorylation on
S293 residue ((A), * p < 0.05 vs. untreated cells) and inhibited Pyruva e Dehydrogenase Kinase (PDK)
activity, as measured spectrophotometrically (B). The suppression of PDK resulted in restoration of
PDH complex and enhanced pyruvate flux to mitochondria. Data presented are representative of those
obtained in three separate experiments.
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cells. The treatment of cells with CA for 24 h caused oxidative stress in mitochondria, as measured
using MitoSox Red (A). The enhanced ROS generation was followed by cell death due to apoptosis
(B) Apoptosis/necrosis was determined by flow cytometry followed by Annexin V/EthD-III double
staining, as described in Materials and Methods. The number of apoptotic/necrotic cells was presented
as a percentage of total cells. CA was used at 100 µM and Metformin (Met) at 10 mM and the cells were
incubated for 24 h in serum-free media. Experiments were repeated three times with similar results
and presented as mean values ± SD.
3.3. CA Activates AMPK and Attenuates Lipid De Novo Biosynthesis in C-4I Cells by Suppression of
Regulatory Enzymes of the Pathway
We explored the ability of CA, Met and combined treatment of compounds to activate AMPK
in C-4I cells after 24 h of incubation. Western blot analysis was employed to find out whether tested
drugs may affect the phosphorylation of the enzyme on the T172 residue. Results showed that CA
and Met/CA activated AMPK while Met failed to phosphorylate the enzyme (Figure 4A, p < 0.05 vs.
untreated control). As presented in Figure 4B, the treatment of cervical carcinoma cells with CA and
Met/CA significantly reduced intracellular ATP level (p < 0.01 vs. untreated control for CA and p < 0.01
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vs. untreated control for Met/CA). CA and Met/CA caused phosphorylation of AMPK downstream
protein Acetyl-CoA Carboxylase 1 (ACC1) and deactivated the enzyme by its phosphorylation at S78,80
(Figure 4A, p < 0.05 vs. untreated control).
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Figure 4. Activation of AMPK by Caffeic Acid (CA) and co-treatment in C-4I cells. Human cervical
carcinoma C-4I cells were grown in serum-free medium and were incubated with Metformin (Met, 10 mM),
CA (100 µM) o both compou ds fo 24 h. Th amounts of enzyme protein in cell lysates were measured
by Western blot analysis and followed by chemiluminescent detection (β-actin was used as the protein
loading control, the details described in Material and Methods). Note that exposition of cells to
CA and Met/CA increased the phosphorylation of AMPK on T172 residue (A). AMPK downstream
protein, Acetyl-CoA Carboxylase 1 (ACC1), was phosphorylated at S78,80 due to CA and et/CA
treatment. The phosphorylation of ACC1 resulted in the decrease of its activity. CA alone and Met/CA
significantly decreased ATP content in cancer cells, as measured with spectrophotometric assay (B)
Data shown her are from a representative experiment repeated three times with similar results, ban
intensities were quantified by densitometry analysis, * p < 0.05 vs. untreated cells (A) or presented as
mean values ± SD for ATP and ADP/ATP (B).
Next, we investigated whether Met and CA may affect the proces of lipid biosynthesis. Therefore,
we tested if the compounds may exert an effect on the expression of regulatory enzymes controlling FA
de novo synthesis, ATP Citrate Lyase (ACLY) and Fatty Acid Synthase (FAS). We found that both drugs
inhibited the expression of ACLY and FAS, but the greatest effect was detected after co-treatment,
as shown in Figure 5A (p < 0.05 vs. untreated control). Additionally, the exposition of cells to CA
and Met/CA reduced Stearoyl-CoA Desaturase-1 (SCD1) protein amount (Figure 5A), which was
followed by a significant decrease in unsaturated FA content in C-4I cells (Figure 5B, p < 0.05 for CA vs.
untreated control, p < 0.01 for Met/CA vs. untreated control)
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Figure 5. Inhibition of ATP Citrate Lyase (ACLY), Fatty Acid Synthase (FAS) and Stearoyl-CoA
Desaturase-1 (SCD1) expression caused by Caffeic Acid (CA), Metformin (Met) and co-treatment and
following decrease in total unsaturated FA content in C-4I cells. Immunoblot analysis (the d tails
described in Materials and Methods) revealing that co-treatment of cells with CA and Met for 24 h
restrained the expression of regulatory enzymes of lipid de novo synthesis ACLY and FAS. Note that
CA, Met and CA/Met downregula ed SCD1, a key enzyme catalyzing the formation of double bond in
FA ((A),* p < 0.05 vs. untreated cells), which was followed by decrease of the level of total unsaturated
FA in C-4I cells, as measured using spectrophotometric assay ((B), mean values ± SD were presented,
n = 3).
3.4. Met Decreases HIF-1α Protein Stability under Hypoxia and Inhibits the Expression of HIF-1α Downstream
Efectors in HTB-35 Cells
To gain more insight into the overall effect of CA and Met on metabolic reprogramming of HTB-35
cells, here we aimed to determine, whether Met may regulate the key points of glycolytic pathway.
In the current study we used C-4I cells and HTB-35 cells for comparative reasons. As HIF-1α plays a
central role in the regulation of glycolytic phenotype of tumor cells [27], we performed Western blot
analysis to test the effect of drugs on HIF-1α under hypoxic and normoxic conditions. We found that
in HTB-35 cells HIF-1α protein was induced under hypoxia, while in normoxic conditions the protein
was not detected (Figure 6A). In C-4I cells hypoxia induced HIF-1α, but we found that the protein was
expressed in normoxia as well. As shown on immunoblots, the exposition of HTB-35 cells the cells
to 10 mM Met suppressed HIF-1α. CA treatment at 100 µM for 24 h also inhibited HIF-1α (p < 0.05
vs. control).
To assess whether Met regulates the expression of HIF-1α-dependent proteins in cervical
cancer cells we performed Western blot analysis. As demonstrated on immunoblots, in hypoxic
HTB-35 cells Met decreased transcript for Glucose transporter 3 (GLUT3), Hexokinase 2 (HK2),
6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 4 (PFKFB4), Pyruvate Kinase (PKM) and
Nutrients 2018, 10, 841 11 of 21
Pyruvate dehydrogenase kinase 1 (PDK 1) under hypoxic conditions. CA exerted weaker effect
on expression of glycolytic regulatory genes in HTB-35 cells (Figure 6B). We detected minor changes in
the protein level for glycolytic enzymes in C4-I cells under CA, Met and co-treatment.
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Figure 6. The effect of Caffeic Acid (CA) and Metformin (Met) on HIF-1α degradation (A) and
expression of glycolytic regulatory proteins (B) in C-4I and HTB-35 cells. The cells were treated for 24 h
with CA (100 µM) and/or Met (10 mM) either in normoxia (21% O2 level) or in hypoxia (5% O2 level).
Protein levels of HIF-1α was analyzed by Western blot and shown in Figure 6A. Note that hypoxia
elevated the amount of HIF-1α protein in HTB-35 cells. Met caused the greatest decrease of HIF-1α
protein level in HTB-35 cells (A). Representative immunoblots show that treatment of HTB-35 cells
with Met during hypoxia decreased protein amounts for Glucose transporter 3 (GLUT3), Hexokinase 2
(HK2), 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 4 (PFKFB4), Pyruvate Kinase (PKM) and
Pyruvate dehydrogenase kinase 1 (PDK 1) ((B), * p < 0.05 vs. untreated cells) Analysis of prot in level
was performed with Western blot (30 µg of protein was loaded on the polyacrylamide gel, the procedure
was described in Material and Methods, β-actin was used as a reference). Experiments were repeated
three times with similar results and presented as mean values ± SD.
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3.5. Met Evokes Apoptosis and Downregulates BCL-2, CCND1 and c-Myc in HTB-35 Cells
We analyzed, if the exposition of the cells to drugs may result in facilitated apoptosis in HTB-35 cells.
As presented in Figure 7A, the incubation of the cells in normoxia with Met at concentration of 10 mM
caused tumor cell death due to apoptosis, as measured using flow cytometry (p < 0.01 vs. untreated
control). Co-treatment caused the greatest increase of apoptotic cells under normoxia and hypoxia (p < 0.01
vs. untreated control for normoxic conditions, p < 0.05 vs. untreated control for hypoxic conditions).
The percent of apoptotic cells in population following Met treatment in hypoxic conditions was higher
than apoptosis detected in normoxia (p < 0.05 Met in normoxia vs. Met in hypoxia).
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Figure 7. The effect of Metformin (Met) and Caffeic Acid (CA) on apoptosis and proliferation in HTB-35
cells. The cells were incubated either in normoxia (21% O2 level) or in hypoxia (5% O2 level) with CA
(100 µM), Met (10 mM) or both compounds for 24 h. Met promoted cell death due to apoptosis ((A),
p < 0.05 vs. control) and inhibited the expression of B-cell lymphoma 2 (BCL-2), Cyclin D1 (CCND1)
and Proto-Oncogene C-Myc (c-Myc) genes in HTB-35 cells (B). Data shown here are representative of
three ex eriments performed with similar results. (A) Apoptosis was determined by flow cytometry
(Annexin V/EthD-III double staini g), (B) the expressi n of mRNA under normoxic and hypoxic
conditions was analyzed with qPCR (the data ere normalized against reference gene Glyceraldehyd
3-phosphate d hydrog nase (GAPDH) transcript; the 2−∆∆Ct method was used for dete mination of
RNA level; * p < 0.05 an # p < 0.01 vs. control).
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As the proteins of Bcl-2 gene family are involved in the apoptotic signaling, we determined if
CA and Met affect the expression of genes encoding BAX and BCL-2 proteins. We used real-time
RT–PCR to analyze the effects at the mRNA level. Apoptosis regulator BAX by interaction with the
mitochondrial voltage-dependent anion channel (VDAC) facilitates to the loss in membrane potential
thereby enabling the release of cytochrome c from mitochondria and following apoptotic death. On the
other hand, Bcl-2 (B-cell lymphoma 2) protein promotes tumor cell survival by inhibiting the actions of
pro-apoptotic proteins. We determined, that under hypoxic and normoxic conditions Met increased
the expression of pro-apoptotic BAX gene and downregulated anti-apoptotic BCL-2 gene (Figure 7B).
Met also suppressed the expression of cyclin-D1 (CCND1). Cyclin-D1 plays the key role in regulation
of the cell cycle progression of cancer cells and in HTB-35 cells exposed to Met the two-fold decrease
of CCND1 transcript level was found under normoxia (p < 0.05 vs. untreated control) and under
hypoxia as well (Figure 8B, p < 0.05 vs. untreated control). Given that c-Myc transcription factor
controls the expression of glycolytic genes and regulates proliferation of tumor cells [28], we examined
the expression of c-Myc in HTB-35 cells. The results showed that Met reduced the mRNA for c-Myc
(p < 0.05 vs. control) in HTB-35 cells exposed to hypoxia and normoxia (Figure 7B).
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Figure 8. CA, Met and co-treatment regulate metabolism of human cervical carcinoma C-4I and
HTB-35/SiHa cells under normoxia and hypoxia. Schematic overview of the cellular effects of the
tested compounds includes aerobic glycolysis and mitochondrial bioenergetics/biosynthetic processes
(the supple entation of TCA cycle by decarboxylation of pyruvate via PDH complex, glutaminolysis of
glutamate via GLS, NAPPH formation via ME1) and the synthesis of unsaturated FA. The main actions
of CA, Met and CA/Met on regulatory proteins and processes wer marked with a rows (↑ activation,
↓ inhibition). The previous results [18] denoted by the asterisk (*).
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4. Discussion
In prior studies we showed that small molecules Met and CA may influence mitochondrial
oxidative metabolism in metastatic human cervical squamous carcinoma cell lines, HTB-35 [18] and
HTB-34 [25]. As the TCA cycle plays a key role in determining of “flexible” metabolic phenotype
of neoplastic cells [1,22,24], here we aimed to gain more insight into the effect of CA and Met on
cellular bioenergetics and biosynthetic capacity of C4-I epithelial cells derived from in situ cervical
tumor. In particular, increased glutaminolysis via GLS effectively replenishes TCA cycle pool for
citrate synthesis [22,28]. Our results show that CA at 100 µM limits TCA cycle supplementation with
glutamine by decreasing GLS expression in C-4I cells. What is more, in tumor cells glutamine entry to
TCA cycle improves not only carbon supply for macromolecules build-up, it also may replenish pool
of cellular NADPH, since the conversion of malate to pyruvate catalyzed by ME1 is accompanied by a
reduction of NADP+ molecule. In cancers, ME1 is active enough to provide sufficient level of reductive
power for lipid biosynthesis [29] and de novo synthesis of cellular phospholipids may be sustained
even if the glycolytic generation of NADPH is shut down [3]. During oxidative stress NADPH play
key role in reinforcing the anti-oxidative protection of tumor cell by the reduction of glutathione
molecules [2]. In the current study CA treatment of C-4I cells causes downregulation of ME1 together
with a significant decrease of NADPH level. Therefore, we may presume that the impaired generation
of NADPH results not only in alleviation of biosynthesis, but also in the reduced ability of tumor cells
to combat ROS generated in oxidative mitochondrial metabolic pathways.
What is more, CA treatment of C-4I cells causes the restoration of PDH “bottleneck”, which
reduces the flux of pyruvate to lactate and additionally disturbs the generation of NADPH and ATP
in cytosol. As a result, pyruvate enters mitochondrial oxidative metabolism via PDH complex [6].
In tumor cells, PDH plays a key role in determining the fate of glucose. A specific PDH kinase
(PDK) phosphorylates and inactivates PDH [2,30]. In culture of HeLa cervical tumor cells, PDK
inhibitor dichloroacetate (DCA) was recently demonstrated to reduce glycolysis by activating PDH [31].
The similar effect of DCA was shown in glioblastoma cell line [32]. The present data suggest that CA
may be another potent PDK inhibitor. In C-4I cells exposed to CA the enhanced fueling of TCA cycle
with pyruvate leads to induction of intolerable oxidative stress and apoptosis (Appendix A). The similar
effect we observed in cervical cancer HTB-34 cells treated with CA, as previously reported [25].
By contrast to C4-I cells, in invasive HTB-35 line Met at 10 mM was shown to activate oxidative
decarboxylation of pyruvate, while CA had no significant effect [18]. The present study provides the
possible explanation for such action of the drugs, since while in C4-I cells CA affects the activity of PDK,
Met in HTB-35 cells targets the expression of gene encoding PDK-1. PDK-1 is a isoenzyme specific to
cancer cells and its expression is controlled by HIF1α [29]. Interestingly, under hypoxic conditions
the downregulation of PDK-1 caused by Met is even greater than during normoxia. Therefore, CA
activates PDH in epithelial C-4I cells and Met in aggressive HTB-35 cells. These findings imply that
both drugs may precisely regulate PDH checkpoint in cervical tumor cell lines and the mechanism of
action depends on the particular metabolic phenotype of the cells.
Our data show that CA and CA/Met treatments reduce intracellular ATP level in C-4I cells
and causes energetic stress followed by AMPK activation. Several reports have suggested that
once activated AMPK may act as a potent metabolic tumor suppressor [33]. However, it was also
found, that AMPK activation and following inhibition of ACC1 may prevent NADPH consumption
and promote survival of cancer cells, as reported by Park et al. [34] and Jeon et al. [35]. Our data
suggest that in C-4I cells in conditions of limited TCA cycle anaplerosis/suppressed generation
of reductive power for biosynthesis/disturbed cellular bioenergetics the activation of AMPK may
result rather in anti-proliferative than pro-survival effect. Phytochemicals-rich strawberry extract
stimulated AMPK and inhibited regulatory proteins of FA and cholesterol synthesis in Hep G2
cells [36]. It was demonstrated in colorectal carcinoma cells and hepatocellular carcinoma cell line that
CA derivatives and Met may suppress tumor cells growth by inhibition of lipid de novo synthesis
involving AMPK signaling [9,37–39]. Sánchez-Martínez et al. reported that activation of AMPK
Nutrients 2018, 10, 841 15 of 21
counteracts the induction of EMT phenotype triggered by the ACSL/SCD signaling network [40].
Interestingly, here the concerted action of the drugs causes the greatest inhibition of FA biosynthesis
as well as cells’ proliferation (Appendix A). The co-treatment affected HTB-35 and HTB-34 cells in
the similar way, thus we may presume that the regulatory points of FA de novo synthesis may be
molecular targets for the drugs. Additionally to our previous results, here we demonstrated that
the exposition of cervical cancer cells to double treatment impaired FA generation via AMPK/ACC1
axis [18,25]. Most notably, in the current study the exposition of the cells to CA, Met and CA/Met
causes almost complete downregulation of SCD1, the enzyme that controls the key step in the synthesis
of unsaturated FA. Considering the essential role of unsaturated FA in cancer cell metabolom, the total
inhibition of unsaturated FA generation under co-treatment may suppress numerous intracellular
processes, such as synthesis of tumor cell membranes. However, the obtained data are not enough
to state that the activation of AMPK and following impairment of lipid synthesis is a conclusive
mechanism restraining proliferation of cervical cancer cells. We will continue the study in order to
elucidate mechanisms underlining this finding.
Likewise, it should be stressed that modulating AMPK in cervical cells may lead to various
outcomes as a result. Thus, understanding the context-dependent effects of AMPK activation in
cervical tumors may be critical to define precisely what kind of manipulation can be therapeutically
beneficial. What is more, several molecular pathways by which AMPK mediate anticancer effects have
been previously recognized. Liver Kinase B1 (LKB1)/AMPK/mTOR signaling is thought to be the
fundamental mechanism behind the suppression of tumor cells proliferation. It was demonstrated,
using biopsies of cervical tumor tissues, that somatic mutations may occur in LKB1 gene in humans,
thereby hampering its function [41,42]. In this case the classical activators of LKB1/AMPK axis might
be inefficient. However, it was also shown, that at the same time LKB1-deficient tumor cells are
more sensitive to energy stress, which provides some opportunities for targeted therapy using small
molecules that disrupt intracellular energy balance [5,15,41]. In line with this finding, CA in epithelial
C4-I cells and Met in motile HTB-35 cells, by targeting energy homeostasis and reducing intermediates
for biosynthesis, may be used for effective shut down of cancer cells growth. Our previous [18] and
the current study have revealed that while CA was more active than Met in C4-I cells, the latter drug
caused massive cell death in HTB-35 cell line (Figure 8).
Here, we tried to recognize the factors related to different cellular effects of the compounds.
Our latest study demonstrated that both cell lines display different epithelial/mesenchymal gene
expression profile [24,42], which may account for their susceptibility to the drugs. It was established
that the activation of glycolysis a prevalent energy source for migrating cells, which undergo EMT to
improve survival in a harsh environment and facilitate metastasis [3]. As the glycolytic phenotype
of tumor cell is triggered mainly by HIF-1α master regulator, we sought to find out, whether the
drugs may exert its effect on metabolic reprogramming of HTB-35 cell via HIF-1α and its downstream
proteins. The overexpression of HIF-1α efficiently supports metabolic reprogramming of tumors [26,43].
Our study showed that Met inhibited hypoxia-induced upregulation of HIF-1α and its downstream
proteins, which was demonstrated using Western blot analysis. Met effectively restrained the
glycolytic phenotype of HTB-35 cells by downregulation of glucose transporters GLUT1 and GLUT3,
by suppressing of HK2, the limiting enzyme of glycolysis, and by inhibiting regulatory enzymes of
the pathway, PFKFB4, PKM and LDH (Figure S1). Under hypoxic conditions inside some tumors,
the activation of HIF-1α restricts glucose and glutamine entry into the TCA cycle by suppressing of
PDH and α-KG dehydrogenase (α-KGDH) activities. Therefore, the triggering of HIF-1α-dependent
program promotes survival of neoplastic cells by decreasing mitochondrial metabolism, adjusting TCA
flux and minimalizing of oxidative stress within mitochondria [44]. Our study shows that in HTB-35
cells Met may counteract these metabolic alterations by decreasing PDK1 gene expression, which leads
to augmented funneling of TCA cycle and results in impairment of glycolysis. It should be clearly
recognized that at the same time the effect of CA on glycolysis in HTB-35 cells was minor.
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Recent studies have reported that enhanced expression of the oncogene c-Myc is involved in
the formation of cervical cancer [28]. Additionally, the upregulated c-Myc may collaborate with HIF
in the induction of glycolytic phenotype of tumor cell, increased glucose consumption, decreased
oxidative phosphorylation and accompanying lactate production [45]. Therefore, we presume that
the downregulation of c-Myc in HTB-35 cells treated with Met and CA/Met may additionally hamper
glycolytic phenotype of the cells. The treatment of HTB-35 cells with Met caused the suppression of
cyclin D1 gene (CCND1), which in most tumor cells is positively regulated by c-Myc. These effects,
together with the upregulation of pro-apoptotic BAX, may facilitate apoptosis in HTB-35 cells.
In C4-I cells CA suppressed c-Myc (Figure S2), GLS expression, and thereby glutamine supply
to TCA cycle. The cells starving glutamine are more sensitive to first apoptosis signal (FAS) receptor
ligands and more vulnerable to death via FAS-dependent extrinsic apoptotic pathway [46]. However,
we did not investigate comprehensively, whether C4-I cells are more susceptible to apoptosis elicited via
external factors following incubation with CA. We only aimed to point out that regulation of metabolic
reprogramming of cervical cancer cells may result in decreased cell survival. As mentioned, the increased
ROS level may trigger cell death via apoptotic intrinsic pathway. It has been reported before that CA
may evoke mitochondrial apoptosis in HeLa cervical tumor cells via inhibiting BCL-2 activity, release of
cytochrome-c from mitochondria and activation of caspase 3 [37,47]. In the current study we have found
that in C4-I cells CA upregulates pro-apoptotic promoter BAX protein (Figure S2). Activation of BAX may
lead to disruption of mitochondrial membrane potential and to a cascade of events leading to apoptotic
cell death. In the present work we have not determined, whether the exposition of C4-I cells to CA may
trigger such intracellular events. However, our data shows that CA suppresses the expression of “primer
oncogene” c-Myc and its downstream gene CCND1. Interestingly, in C4-I cells Western blot analysis
revealed the elevated expression of HIF-1α protein even during normoxia and we assume that the process
of induction of HIF-1α-dependent genes may be altered. This finding provides possible explanation for a
minor effect of CA and Met on glycolytic pathway in C4-I cells.
In our previous and present experimental models, CA was used at a relatively high concentration
(100 µM) whereas the micromolar concentration of CA is rather transient following oral application
in humans [6]. Met was used at a concentration of 10 mM, while plasma concentration of the drug
after single oral administration in diabetic patients is around 200-fold less [48]. However, it has been
demonstrated that Met may accumulate in mitochondrial matrix even 1000-fold more than average
level measured in human blood [49]. We can hypothesize that the location of cervical cancer within
the body provides the opportunity to use the topical formulation containing the drugs at adequate
concentration to evoke the anti-tumor effect. The topical ointment formulation of catechins was
approved by The United States Food and Drug Administration for virucidal use in humans, and the
relevant preventive effect of polyphenols against HPV infection has been demonstrated before [50].
Additionally, CA and Met can synergize with targeted therapies to enhance therapeutic response in
specific tumor types [17,18]. Karthikeyan et al. reported that ferulic acid improved the outcome of
radiation therapy against human cervical carcinoma cells [51]. CA pre-treatment sensitized ovarian
cancer cells to the cytotoxic activity of cisplatin [16]. Met enhanced the action of tamoxifen in breast
cancer [17]. As discussed elsewhere, CA and Met are absorbed and metabolized by cancer cells [6,11]
and are not toxic to normal cells [18] However, our data show that Met may to a small extent reverse
CA-dependent GLS inhibition in C4-I cell line. The mechanism of such an effect is not clear, since
our current data showed that c-Myc, the oncogene that controls GLS expression, was not activated by
Met. The underlined mechanism is probably more complex, and we cannot elucidate it based only
on existing observations. However, this study may provide more insights into the existing results on
the action of the drugs in cervical cancer cells and the treatment using tested drugs in vivo should
be carefully considered, especially against the tumor cells that are glutamine-addicted. We may also
presume, that the high amounts of nutrients in cell culture medium in present experiments, especially
glutamine, might have extremely supported cancer cell growth and the effect of compounds in vivo
may be different comparing to in vitro conditions [41,48].
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5. Conclusions
The present study provides evidence that CA and Met induce energetic stress and impair the
generation of reductive power for biosynthesis and anti-oxidative protection of cervical cancer cells.
Additionally, each compound triggers specific mechanisms in the cells expressing epithelial and
mesenchymal phenotypes. CA funnels carbon flux towards the TCA cycle which results in upregulation
of ROS production and decreased survival of epithelial C4-I cells. Met acts as a glycolytic inhibitor
under normoxic and hypoxic conditions via the downregulation of HIF1α and c-Myc in aggressive
HTB-35 cells which undergo EMT. The use of both compounds may be therapeutically beneficial against
invasive cervical tumor cells such as HTB-35 line, while the effect of co-treatment on mitochondrial
regulatory enzymes in C4-I cells is minor. Application of CA and Met in humans may provide a
promising approach in the prevention of cervical cancer progression regarding specific phenotypes of
cells and in respect of metabolic and genetic profiles of tumor cells.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/2072-6643/10/7/
841/s1. Figure S1: Met downregulates transcripts for glycolytic enzymes in HTB-35 cells. The cells were treated
for 24 h with CA (100 µM) and/or Met (10 mM) either in normoxia (21% O2 level) or in hypoxia (5% O2 level).
RT-PCR analysis was used and HPRT1 was a reference gene. Experiments were repeated three times with similar
results and presented as mean values ± SD, Figure S2: The effect of Metformin (Met) and Caffeic Acid (CA) on
expression of BAX, BCL-2, c-Myc and CCND1 genes in C-4I cells. The cells were incubated either in normoxia
(21% O2 level) or in hypoxia (5% O2 level) with CA (100 µM), Met (10 mM) or both compounds for 24 h. CA
inhibited the expression of CCND1 and c-Myc and CA/Met suppressed BCL-2 gene in HTB-35 cells (B). Data
shown here are representative of three experiments performed with similar results. qPCR analysis was performed
to assess the expression of mRNA under normoxic and hypoxic conditions. For qPCR the data were normalized
against GAPDH transcript as a reference gene and levels of RNA expression were determined with the 2−∆∆Ct
method (* p < 0.05 vs. control).
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AMPK 5′-adenosine monophosphate-activated protein kinase
ACC1 Acetyl-CoA Carboxylase 1
ACLY ATP Citrate Lyase
FAS Fatty Acid Synthase
SCD1 Stearoyl-CoA Desaturase-1
GLUT1 Glucose transporter 1
PDH Pyruvate Dehydrogenase Complex
PDK Pyruvate Dehydrogenase Kinase
GLS Glutaminase
ME1 Malic Enzyme 1
ETC Electron Transport Chain
OXPHOS Oxidative Phosphorylation
ROS Reactive Oxygen Species
PPP Pentose Phosphate Pathway
NADPH Nicotinamide adenine dinucleotide phosphate, reduced form
NADP Nicotinamide adenine dinucleotide phosphate, oxidized form
NADPH Nicotinamide adenine dinucleotide phosphate, reduced form
ATP Adenosine triphosphate
AMP Adenosine monophosphate
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EMT Epithelial-Mesenchymal Transition
VDAC voltage-dependent anion channel
FAS receptor first apoptosis signal receptor
Appendix A
CA at concentrations ranged from 100 µM to 10 mM significantly inhibited proliferation of C-4I cervical
carcinoma cells (p < 0.05 vs. untreated control for 100 µM, p < 0.01 vs. untreated control for 1 mM, 5 mM, 10 mM),
as measured with MTT assay, and Met significantly decreased the viability of cells at 50 mM and 100 mM (p < 0.01
vs. untreated cells, Figure A1A,B, respectively). In present experiments CA at 100 µM and co-treatment of CA
with Met at 10 mM inhibited proliferation (p < 0.05 vs. control and p < 0.01 vs. control) and growth of C-4I
cells, compared with untreated control (Figure A1C,D, respectively). Likewise, the presence of CA and also the
combination of CA and Met in culture medium caused cytotoxicity (p < 0.01 vs. control and p < 0.01 vs. control,
Figure A1E) and aggravated cell morphology comparing to untreated cells, as shown in Figure A1F.
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Figure A1. Inhibitory effect of CA treatment on proliferation and growth of C-4I cells. Cervical
carcinoma cells were cultured in serum-free medium and exposed to Met at concentration ranged from
100 µM to 100 mM for 24 h. The anti-proliferative activity of CA was assessed using MTT colorimetric
assay (A). The untreated cells were controls. The ef ct of M t was tested and measured in th ame
experimental conditions (B). After incubation of C4-I cells with mixture of 100 µM of CA and 10 mM of
Met, the proliferation of cells was inhibited compared to untreated cells, (p < 0.01) (C). The decrease of
the number of cells after Met/CA treatment was also assessed (using automatic cell counter, * p < 0.05
and # p < 0.01 vs. control) (D). LDH col rim tric ass y revealed that CA and M t/CA were cytotoxic to
C-4I cells (p < 0.01 vs. untreated cells) (E) and aggravated the morphology of monolayers, as shown in
phase contrast microphotographs (F).
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